Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 ends flat as healthcare, commodity-linked stocks weigh; ends month higher

Mon, 31st Jan 2022 09:23

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Vodafone among top FTSE 100 gainers

* Recruiter SThree gains after annual profit doubles

* Online estate agency Purplebricks forecasts growth in 2023

* FTSE 100 flat, FTSE 250 adds 1.3%
(Updates to close)

By Shashank Nayar

Jan 31 (Reuters) - London's FTSE 100 erased early gains to
end flat on Monday as weakness in healthcare and
commodity-linked shares countered advances in financials, while
the index recorded its second consecutive monthly increase.

After rising as much as 0.8%, the blue-chip FTSE 100 index
ended flat, with Rio Tinto, Anglo American
, Glencore and AstraZeneca among top
drags.

The FTSE 100 ended the month 1.1% higher, significantly
outperforming the wider European stock aggregate, which
recorded its worst month since October 2020.

Investors now await a key monetary policy decision from the
Bank of England due later this week where expectations are for a
50-basis-point rate hike, its second hike in a row, as it looks
to tame rising inflation pressure.

"There are some concerns about the hit to disposable income
from the surge in inflation coming in the spring, but this might
just redouble the committee's (MPC) resolve to bring it back
under control," according to Brian Hillard, chief UK economist
at Societe General.

Leading gains were the insurance and
industrial stocks, up 0.6% and 1.3% respectively.

Vodafone Group PLC was among the top FTSE 100
gainers, up 1.9%, after saying it would work with Intel Corp
and other silicon vendors on designing its own chip
architecture to drive innovation and efficiency in nascent
OpenRAN network technology.

The FTSE 100 has been helped by a robust performance in
higher weighted banking and energy shares on expectations of
rising interest rates and soaring oil prices, respectively, and
a lower representation of technology stocks that do not perform
well in a high-interest scenario.

The domestically focussed mid-cap index rose 1.3%
with travel and leisure stocks gaining the most.

Among stocks, British recruiting firm SThree
jumped 12.6% after its annual profit nearly doubled.

Britain's biggest online-only estate agency, Purplebricks
Group rose 1.3% following its forecast of a return to
growth in 2023, after it posted a half-year loss hurt by charges
related to "process issues".-0.5
(Reporting by Shashank Nayar and Amal S in Bengaluru; Editing
by Shailesh Kuber, William Maclean)

More News
Today 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
Today 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.